Gout.
Conditions
Interventions
All included patients will receive anakinra, 100 mg o.d. by subcutaneous
injection for 3 consecutive days. The first injection needs to be administred
within 24 hours after the acute attack is first
Sponsors
Jan van Breemen Instituut
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with a crystal-confirmed diagnosis of gout Patients with known intolerance or contra-indications for colchicine and NSAIDs and relative contra-indications to systemic prednisolone. Patients with a currently acute gout flare
Exclusion criteria
Exclusion criteria: Patients with latent (or active) tuberculosis, Positive serology for hepatitis B or C, Patients with diabetes mellitus, Patients with an extended history of cardiovascular disease Patients s with a creatinine clearance less than 30 ml/min Patients willing to receive an standard treatment conform the ACR guidelines 2012 and who do not agree to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The reduction in VAS (Visual Analog Scale) pain after 72 hours of anakinra treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| The changes in markers of inflammation and endothelial function, changes in arterial stiffness and microcirculation after 7 and 21 days of treatment with anakinra. | — |
Countries
Netherlands
Outcome results
None listed